2. Academic Validation
  3. A second life for MAO inhibitors? From CNS diseases to anticancer therapy

A second life for MAO inhibitors? From CNS diseases to anticancer therapy

  • Eur J Med Chem. 2024 Mar 5:267:116180. doi: 10.1016/j.ejmech.2024.116180.
Sabina Sblano 1,  Angelina Boccarelli 2,  Francesco Mesiti 1,  Rosa Purgatorio 1,  Modesto de Candia 1,  Marco Catto 3,  Cosimo D Altomare 1
Affiliations

Affiliations

  • 1 Department of Pharmacy-Pharmaceutical Sciences, University of Bari Aldo Moro, Via E. Orabona 4, 70125, Bari, Italy.
  • 2 Department of Precision and Regenerative Medicine and Ionian Area, School of Medicine, University of Bari Aldo Moro, Piazza Giulio Cesare 11, 70124, Bari, Italy. Electronic address: [email protected].
  • 3 Department of Pharmacy-Pharmaceutical Sciences, University of Bari Aldo Moro, Via E. Orabona 4, 70125, Bari, Italy. Electronic address: [email protected].
PMID: 38290352 DOI: 10.1016/j.ejmech.2024.116180
Abstract

Monoamine oxidases A and B (MAO A, B) are ubiquitous Enzymes responsible for oxidative deamination of amine neurotransmitters and xenobiotics. Despite decades of studies, MAO inhibitors (MAOIs) find today limited therapeutic space as second-line drugs for the treatment of depression and Parkinson's disease. In recent years, a renewed interest in MAOIs has been raised up by several studies investigating the role of MAOs, particularly MAO A, in tumor insurgence and progression, and the efficacy of MAOIs as coadjutants in the therapy of chemoresistant tumors. In this survey, we highlight the implication of MAOs in the biochemical pathways of tumorigenesis and review the state-of-the-art of preclinical and clinical studies of MAOIs as Anticancer agents used in monotherapy or in combination with antitumor chemotherapeutics.

Keywords

Antitumor chemotherapy; Inhibitors; Monoamine oxidase; Neuroprotection; Tumorigenesis.

Figures